Spa Executive

JULY 17, 2024

It excels in addressing specific needs such as targeted treatments, accommodating preferences for privacy or time constraints, and catering to guests who may prefer alternatives to traditional hands-on therapies. However, the essence of luxury service lies in the personal connection forged between guests and skilled spa professionals.

Technology 98

Technology Hospital Sustainability Innovations 98

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. Liu Yi, Sisram Chairman and Executive Director, in a news release.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. The study enrolled 40 healthy adult participants into three single-ascending dose (SAD) and two multiple-ascending dose (MAD) cohorts.

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74

The Dermatology Digest

DECEMBER 5, 2024

Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13.

Portfolios 74

Portfolios Dermatitis Sustainability Injections 74

The Dermatology Digest

FEBRUARY 26, 2025

The data highlight the efficacy of the cream, along with its favorable safety and tolerability profile, which are critical when prescribing a long-term treatment for children with AD, says Mercedes E. In clinical trials, investigational ZORYVE cream 0.05% has shown significant positive results in treating AD in children 2 to 5 years old.

Safety 36

Safety Dermatitis Portfolios Clinic 36